MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1766-1772. doi: 10.15585/mmwr.mm705152a3.
During June 2021, the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating strain in the United States. U.S. pediatric COVID-19-related hospitalizations increased during July-August 2021 following emergence of the Delta variant and peaked in September 2021. As of May 12, 2021, CDC recommended COVID-19 vaccinations for persons aged ≥12 years, and on November 2, 2021, COVID-19 vaccinations were recommended for persons aged 5-11 years.** To date, clinical signs and symptoms, illness course, and factors contributing to hospitalizations during the period of Delta predominance have not been well described in pediatric patients. CDC partnered with six children's hospitals to review medical record data for patients aged <18 years with COVID-19-related hospitalizations during July-August 2021. Among 915 patients identified, 713 (77.9%) were hospitalized for COVID-19 (acute COVID-19 as the primary or contributing reason for hospitalization), 177 (19.3%) had incidental positive SARS-CoV-2 test results (asymptomatic or mild infection unrelated to the reason for hospitalization), and 25 (2.7%) had multisystem inflammatory syndrome in children (MIS-C), a rare but serious inflammatory condition associated with COVID-19. Among the 713 patients hospitalized for COVID-19, 24.7% were aged <1 year, 17.1% were aged 1-4 years, 20.1% were aged 5-11 years, and 38.1% were aged 12-17 years. Approximately two thirds of patients (67.5%) had one or more underlying medical conditions, with obesity being the most common (32.4%); among patients aged 12-17 years, 61.4% had obesity. Among patients hospitalized for COVID-19, 15.8% had a viral coinfection (66.4% of whom had respiratory syncytial virus [RSV] infection). Approximately one third (33.9%) of patients aged <5 years hospitalized for COVID-19 had a viral coinfection. Among 272 vaccine-eligible (aged 12-17 years) patients hospitalized for COVID-19, one (0.4%) was fully vaccinated.*** Approximately one half (54.0%) of patients hospitalized for COVID-19 received oxygen support, 29.5% were admitted to the intensive care unit (ICU), and 1.5% died; of those requiring respiratory support, 14.5% required invasive mechanical ventilation (IMV). Among pediatric patients with COVID-19-related hospitalizations, many had severe illness and viral coinfections, and few vaccine-eligible patients hospitalized for COVID-19 were vaccinated, highlighting the importance of vaccination for those aged ≥5 years and other prevention strategies to protect children and adolescents from COVID-19, particularly those with underlying medical conditions.
2021 年 6 月,导致 COVID-19 的 SARS-CoV-2 病毒的高度传染性 B.1.617.2(德尔塔)变体成为美国主要传播的病毒株。2021 年 7 月至 8 月,德尔塔变体出现后,美国与 COVID-19 相关的儿科住院人数增加,并在 2021 年 9 月达到高峰。截至 2021 年 5 月 12 日,CDC 建议≥12 岁的人接种 COVID-19 疫苗,2021 年 11 月 2 日,建议 5-11 岁的人接种 COVID-19 疫苗。**迄今为止,德尔塔优势期间儿科患者的临床症状和体征、疾病过程以及导致住院的因素尚未得到很好的描述。CDC 与六家儿童医院合作,审查了 2021 年 7 月至 8 月期间因 COVID-19 相关住院的<18 岁患者的医疗记录数据。在确定的 915 名患者中,713 名(77.9%)因 COVID-19 住院(急性 COVID-19 是住院的主要或促成原因),177 名(19.3%)有偶然的 SARS-CoV-2 检测结果阳性(无症状或与住院原因无关的轻度感染),25 名(2.7%)有多系统炎症综合征(MIS-C),这是一种罕见但与 COVID-19 相关的严重炎症疾病。在因 COVID-19 住院的 713 名患者中,24.7%的年龄<1 岁,17.1%的年龄为 1-4 岁,20.1%的年龄为 5-11 岁,38.1%的年龄为 12-17 岁。大约三分之二的患者(67.5%)有一个或多个基础疾病,肥胖是最常见的(32.4%);在 12-17 岁的患者中,61.4%肥胖。在因 COVID-19 住院的患者中,15.8%有病毒合并感染(其中 66.4%有呼吸道合胞病毒[RSV]感染)。大约三分之一(33.9%)<5 岁因 COVID-19 住院的患者有病毒合并感染。在 272 名有资格接种疫苗(年龄 12-17 岁)的因 COVID-19 住院的患者中,有 1 名(0.4%)完全接种了疫苗。***大约一半(54.0%)因 COVID-19 住院的患者接受了氧气支持,29.5%住进了重症监护病房(ICU),1.5%死亡;需要呼吸支持的患者中,14.5%需要有创机械通气(IMV)。在因 COVID-19 住院的儿科患者中,许多患者病情严重,且有病毒合并感染,很少有资格接种 COVID-19 疫苗的患者接种了疫苗,这突出表明对于≥5 岁的人群以及其他预防策略接种疫苗的重要性,以保护儿童和青少年免受 COVID-19 的侵害,特别是那些有基础疾病的患者。